Founded in 2011, Elicio Therapeutics Inc. strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors.
Elicio’s proprietary Amphiphile or “AMP” platform differentiates the company through the development of cancer immunotherapies for patients with limited treatment options and often poor outcomes.
As the foundation for the various vaccine candidates in the biotech company’s pipeline, the AMP platform will help Elicio combat cancer and other diseases.
Elicio’s proprietary Amphiphile or “AMP” platform differentiates the company through the development of cancer immunotherapies for patients with limited treatment options and often poor outcomes.
As the foundation for the various vaccine candidates in the biotech company’s pipeline, the AMP platform will help Elicio combat cancer and other diseases.
Category
🗞
NewsTranscript
00:00 Elisio's proprietary Amphiphile, or AMP, platform differentiates the company through
00:06 the development of cancer immunotherapies for patients with limited treatment options
00:10 and often poor outcomes.
00:12 As the foundation for the various vaccine candidates in the biotech company's pipeline,
00:15 the AMP platform will help Elisio combat cancer and other diseases.
00:20 The platform was first developed in the lab of Daryl Irvine, PhD, whose work as a Howard
00:24 Hughes Medical Institute investigator and professor at the Koch Institute for Integrative
00:28 Cancer Research at MIT has put him at the forefront of the field.
00:32 A clinical-stage biotechnology company, Elisio Therapeutics has developed multiple cancer
00:36 vaccine candidates, including ELI002 for CRAS-driven cancers caused by a mutation of the CRAS
00:42 gene, ELI007 for cancers involving mutant BRAF gene, and ELI008 for cancers involving
00:48 p53 hotspot mutations.
00:50 Preclinical trials have shown that Amphiphiles target and concentrate an array of different
00:54 immunogens in the lymph nodes, resulting in tumor or pathogen-targeted immunity.
00:59 And one trial on Elisio Therapeutics' vaccine was given to patients with pancreatic and
01:03 colorectal cancers.
01:04 The results were promising, with 77% of patients experiencing a reduction in biomarkers that
01:09 show the persistence of tumors.
01:11 32% of patients completely cleared those biomarkers.
01:14 Elisio Therapeutics seems to be leading the charge towards vaccination against cancer.
01:18 By combining expertise in immunology and immunotherapy, Elisio is precisely targeting and fully engaging
01:24 the lymph nodes, the site in our bodies where the immune response to cancer is orchestrated.
01:28 (upbeat music)